<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02524262</url>
  </required_header>
  <id_info>
    <org_study_id>620070-SWE-2012</org_study_id>
    <nct_id>NCT02524262</nct_id>
  </id_info>
  <brief_title>L-cysteine Prevents Stomach Exposure to Carcinogenic Acetaldehyde</brief_title>
  <official_title>Slow-release L-cysteine Capsule Prevents Carcinogenic Gastric Acetaldehyde Exposure in Helicobacter-associated Atrophic Gastritis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Per Hellström</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Biohit Oyj, Helsinki, Finland</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Helsinki University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Åbo Akademi University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Clinical Trial Consultants, Uppsala, Sweden</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Uppsala University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Atrophic gastritis with hypochlorhydric milieu is a risk factor for gastric cancer. Microbes
      colonizing the acid-free stomach oxidize ethanol into acetaldehyde, a group 1 carcinogen. The
      aim is to assess gastric production of acetaldehyde and its inert condensation product,
      non-toxic 4-methyltiazolidine-2-carboxylic acid (MTCA), after alcohol intake under treatment
      with slow-release L-cysteine or placebo.

      Patients with biopsy-confirmed atrophic gastritis, low serum pepsinogen and high gastrin-17
      are studied. On separate days, patients will be randomly assigned to receive 200 mg
      slow-release L-cysteine or placebo, then have intragastric instillation of 15% (0.3 g/kg)
      ethanol. After intake, gastric concentrations of acetaldehyde, ethanol, L-cysteine and MTCA
      are analysed for 4 hours.

      Expected results show mitigated exposure of the gastric mucosa to acetaldehyde.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Gastric infection with Helicobacter pylori induces chronic active gastritis which over the
      years develop atrophic gastritis with a hypochlorhydric milieu which is a risk factor for
      gastric cancer. Microbes colonizing acid-free stomach oxidize ethanol into acetaldehyde,
      considered a group 1 carcinogen.

      The aim of the study is to assess the gastric production of acetaldehyde and its inert
      condensation product, non-toxic 4-methyltiazolidine-2-carboxylic acid (MTCA), after alcohol
      intake under treatment with slow-release L-cysteine. Identical placebo tablets will be used
      for comparison.

      Patients with biopsy-confirmed atrophic gastritis, low serum pepsinogen and high gastrin-17
      will be studied with case-control design. All subjects will be their own control. On separate
      days, patients are randomly assigned to receive 200 mg slow-release L-cysteine or placebo,
      then have intragastric instillation of 15% (0.3 g/kg) ethanol (corresponding to two glasses
      of wine). After intake, gastric sampling of fluid for a period of four hours is done and
      concentrations of acetaldehyde, ethanol, L-cysteine and MTCA are analysed.

      L-cysteine is expected to decrease gastric acetaldehyde concentrations and increase the MTCA
      level. Gastric L-cysteine and MTCA concentrations are expected to be maintained over the
      study period. With placebo, acetaldehyde is expected to be elevated along with ethanol
      concentrations.

      Based on these assumptions slow-release L-cysteine binds acetaldehyde to form inactive MTCA,
      which remains in gastric juice resulting in reduced local exposure of the gastric mucosa to
      carcinogenic acetaldehyde.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>December 2012</start_date>
  <completion_date type="Actual">September 2015</completion_date>
  <primary_completion_date type="Actual">September 2015</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Acetaldehyde concentrations in the stomach</measure>
    <time_frame>4 hours</time_frame>
    <description>Binding of acetaldehyde to L-cysteine</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>4-methyltiazolidine-2-carboxylic acid concentration in the stomach</measure>
    <time_frame>4 hours</time_frame>
    <description>Production of inert 4-methyltiazolidine-2-carboxylic acid after binding to L-cysteine</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">8</enrollment>
  <condition>Gastritis, Atrophic</condition>
  <arm_group>
    <arm_group_label>Slow-release L-cysteine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Oral intake of slow-release L-cysteine 200 mg before challenge with ethanol.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Oral intake of identically-looking placebo capsules</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Slow-release L-cysteine</intervention_name>
    <description>Bind and inactivate acetaldehyde formed from ethanol by covalent binding to L-cysteine</description>
    <arm_group_label>Slow-release L-cysteine</arm_group_label>
    <arm_group_label>Placebo</arm_group_label>
    <other_name>Acetium</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Helicobacter-associated chronic gastritis

          -  Hypochlorhydria

          -  Hypergastrinemia

          -  Hypopepsinogenemia

        Exclusion Criteria:

          -  Active peptic ulcer disease

          -  Other inflammatory gastrointestinal disease

          -  Gastrointestinal bleeding

          -  Gastrointestinal surgery

          -  Neurological disease

          -  Alcohol abuse

          -  Mental disorder

          -  Not able to sign informed consent
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Per M Hellstrom, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Uppsala University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Uppsala University</name>
      <address>
        <city>Uppsala</city>
        <state>Uppsala county</state>
        <zip>75185</zip>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Sweden</country>
  </location_countries>
  <verification_date>January 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 13, 2015</study_first_submitted>
  <study_first_submitted_qc>August 13, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 14, 2015</study_first_posted>
  <last_update_submitted>January 21, 2016</last_update_submitted>
  <last_update_submitted_qc>January 21, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 25, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Uppsala University</investigator_affiliation>
    <investigator_full_name>Per Hellström</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <keyword>atrohpic gastritis</keyword>
  <keyword>acetaldehyde</keyword>
  <keyword>ethanol</keyword>
  <keyword>L-cysteine</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Atrophy</mesh_term>
    <mesh_term>Gastritis</mesh_term>
    <mesh_term>Gastritis, Atrophic</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ethanol</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>World J Gastroenterol</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

